William Blair & Company
HZNP

William Blair & Company’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

William Blair & Company’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,521
Closed -$362K – 1876
2023
Q2 		$362K Buy
3,521
+205
+6% +$21.6K ﹤0.01% 1178
2023
Q1 		$362K Sell
3,316
-3,982
-55% -$440K ﹤0.01% 1160
2022
Q4 		$831K Sell
7,298
-6,701
-48% -$557K ﹤0.01% 886
2022
Q3 		$866K Sell
13,999
-2,705
-16% -$189K ﹤0.01% 863
2022
Q2 		$1.33M Sell
16,704
-2,253
-12% -$213K 0.01% 750
2022
Q1 		$1.99M Sell
18,957
-2,099
-10% -$205K 0.01% 698
2021
Q4 		$2.27M Sell
21,056
-2,954
-12% -$322K 0.01% 695
2021
Q3 		$2.63M Sell
24,010
-4,321
-15% -$449K 0.01% 627
2021
Q2 		$2.65M Buy
28,331
+373
+1% +$34.3K 0.01% 619
2021
Q1 		$2.57M Sell
27,958
-2,263
-7% -$191K 0.01% 607
2020
Q4 		$2.21M Sell
30,221
-304
-1% -$22.6K 0.01% 620
2020
Q3 		$2.37M Sell
30,525
-5,617
-16% -$386K 0.01% 549
2020
Q2 		$2.01M Sell
36,142
-5,022
-12% -$215K 0.01% 553
2020
Q1 		$1.22M Sell
41,164
-6,311
-13% -$214K 0.01% 622
2019
Q4 		$1.72M Buy
47,475
+35,817
+307% +$1.1M 0.01% 646
2019
Q3 		$317K Sell
11,658
-1,275
-10% -$33K ﹤0.01% 1096
2019
Q2 		$311K Buy
12,933
+3,473
+37% +$88.1K ﹤0.01% 1142
2019
Q1 		$250K Buy
+9,460
New +$224K ﹤0.01% 1218
2018
Q4 		– Sell
-24,863
Closed -$487K – 1826
2018
Q3 		$487K Hold
24,863
– – ﹤0.01% 964
2018
Q2 		$412K Buy
24,863
+676
+3% +$10.3K ﹤0.01% 1015
2018
Q1 		$343K Sell
24,187
-28,630
-54% -$423K ﹤0.01% 1037
2017
Q4 		$771K Buy
52,817
+3,402
+7% +$47.8K 0.01% 816
2017
Q3 		$627K Buy
49,415
+14,090
+40% +$179K ﹤0.01% 861
2017
Q2 		$419K Buy
+35,325
New +$439K ﹤0.01% 1042
2017
Q1 		– Sell
-20,460
Closed -$331K – 1528
2016
Q4 		$331K Buy
+20,460
New +$371K ﹤0.01% 959
2015
Q3 		– Sell
-13,015
Closed -$452K – 1602
2015
Q2 		$452K Buy
+13,015
New +$397K ﹤0.01% 1792

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

William Blair & Company's HZNP Position: Q3 2023 in Review

William Blair & Company sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 3,521 shares — an estimated $362K sold.

William Blair & Company first reported a position in HZNP in Q2 2015 and held it in 26 quarters. The position peaked at $2.65M in Q2 2021. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

  • William Blair & Company reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
  • William Blair & Company sold 3,521 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $362K.
  • William Blair & Company first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2015 and held it in 26 quarters.
  • William Blair & Company's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.65M in Q2 2021.
  • 485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on William Blair & Company's 13F filing for Q3 2023, filed 9 Nov 2023.